Arvinas, Inc. (ARVN) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

9/25

Growth 1 Margin 1 Expansion 4 Platform 1 Financial 2

latest quarter score

Earnings Reports

9
Arvinas (ARVN) Q2 2026: $249M Revenue Surge as Pipeline Refocus Drives Cash Runway Into 2028
August 04, 2026
9
Arvinas (ARVN) Q1 2026: R&D Expenses Down 32% as Pipeline Refocuses Post-Vepinu Approval
May 12, 2026
9
Arvinas (ARVN) Q4 2025: R&D Spend Down 18%, Pivots to Four-Program Clinical Focus with Data Milestones Ahead
February 25, 2026
9
Arvinas (ARVN) Q3 2025: $100M Buyback, Cost Reset Extends Cash Runway to 2028
November 05, 2025
8
Arvinas (ARVN) Q2 2025: $25M R&D Cut Reshapes Pipeline, Extends Cash Runway Beyond 2028
August 06, 2025
8
Arvinas (ARVN) Q1 2025: $80M Cost Cuts Reshape Pipeline and Extend Cash Runway
July 04, 2025
Arvinas (ARVN) Q3 2024: Novartis Deal Adds $76.7M Revenue as Phase 3 VetDeg Data Nears Inflection
October 30, 2024

Browse all companies